Center for Therapeutic Antibody Development (CTAD)
The mission of the Center for Therapeutic Antibody Development (CTAD) is to collaborate with researchers in the design and development of monoclonal antibodies (mAbs) for research and commercialization. Because of their sensitivity and specificity, mAbs are critical basic science research tools and are the core technology for many diagnostic tests such as those used to verify pregnancy or influenza infection. In the past decade, mAbs have become the most successful new drug classification with yearly sales exceeding fifty billion dollars. If monoclonal antibodies are needed for basic science studies/grant submission for therapeutic or diagnostics use, please contact us for a consultation to determine the best approach to producing the antibody of interest.
CTAD can help with the generation of protein Immunogens using a number of expression systems. If the antibody has therapeutic value, we can arrange to have it humanized for potential use as a drug. Human antibodies from patient/subject blood can also be produced in many instances.
Thomas M. Moran, PhD, is the Director of the Center for Therapeutic Antibody Development and a Professor of Microbiology at the Icahn School of Medicine. Read More
The Center for Therapeutic Antibody Development facility utilizes molecular technology to generate V gene clones from the isolated monoclonal antibody producing B cells. Learn More